Cullinan Therapeutics, Inc. (CGEM)
NASDAQ · Healthcare
$17.50-1.07%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.09B
- P/E ratio
- —
- EPS
- —
- Volume
- 467,075
- 52-week high
- —
- 52-week low
- —
- Open
- $17.76
- Day high
- $18.38
- Day low
- $17.48
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$219.88M | — |
| 2024 | — | -$167.38M | — |
| 2023 | — | -$153.16M | -$3.69 |
| 2022 | $0 | $111.21M | $2.38 |
| 2021 | $18.94M | -$65.57M | -$1.52 |
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
- CEO
- Nadim Ahmed
- Employees
- 109
- Country
- US
- IPO date
- Jan 8, 2021
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Cullinan Therapeutics, Inc.'s stock price today?
- CGEM is trading at $17.50 as of Jul 20, 2026.
- What is Cullinan Therapeutics, Inc.'s market cap?
- Cullinan Therapeutics, Inc. (CGEM) has a market capitalization of $1.09B.
- Does Cullinan Therapeutics, Inc. pay a dividend?
- Cullinan Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Cullinan Therapeutics, Inc. in?
- Cullinan Therapeutics, Inc. operates in the Healthcare sector.